Skip to content
Disclosery

CAXTON CORP

Follow

13F filer, CIK 1388551, Princeton, NJ

CAXTON CORP reported $4,279,210 across 11 holdings for the quarter ended 2025-12-31, in a 13F-HR filed 2026-02-13. Its ten largest share positions make up 99.37% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000919574-26-000956

Changes against Q3 2025 are not shown: its report omitted holdings under a confidential treatment request (12 positions on file), so every position would read as new.

The filing omits holdings under a confidential treatment request (H8). A later amendment may add them.

Period
2025-12-31
Reported value
$4.28M
Holdings
11
Top 10 weight
99.37%
New
Sold out

Holdings, Q4 2025

Share positions as resolved from 13F-HR 0000919574-26-000956, largest first. % of portfolio is the value over $4,279,210, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
GLDSPDR GOLD TRQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 1,169 shares; 2025Q1: 1,298 shares; 2025Q2: 4,952 shares; 2025Q3: 7,286 shares; 2025Q4: 6,964 shares 6,964$2.76M64.5%The filing omitted confidential holdings, a later amendment may add them.Timeline
BRK-BBERKSHIRE HATHAWAY INC DELQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,151 shares; 2024Q4: 1,133 shares; 2025Q1: 467 shares; 2025Q2: 632 shares; 2025Q3: 651 shares; 2025Q4: 710 shares 710$357K8.34%The filing omitted confidential holdings, a later amendment may add them.Timeline
SYRESPYRE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 8,919 shares 8,919$292K6.83%The filing omitted confidential holdings, a later amendment may add them.Timeline
MIND MEDICINE MINDMED INCMIND MEDICINE MINDMED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 34,073 shares; 2024Q4: 34,073 shares; 2025Q1: 34,073 shares; 2025Q2: 34,073 shares; 2025Q3: 27,011 shares; 2025Q4: 15,688 shares 15,688$210K4.91%The filing omitted confidential holdings, a later amendment may add them.
KYTXKYVERNA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 22,981 shares; 2024Q4: 22,981 shares; 2025Q1: 22,981 shares; 2025Q2: 22,981 shares; 2025Q3: 22,981 shares; 2025Q4: 18,773 shares 18,773$176K4.12%The filing omitted confidential holdings, a later amendment may add them.Timeline
CMPXCOMPASS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 43,465 shares; 2024Q4: 43,465 shares; 2025Q1: 43,465 shares; 2025Q2: 43,465 shares; 2025Q3: 53,503 shares; 2025Q4: 29,495 shares 29,495$158K3.7%The filing omitted confidential holdings, a later amendment may add them.Timeline
LXEOLEXEO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 17,851 shares; 2024Q4: 17,851 shares; 2025Q1: 17,851 shares; 2025Q2: 17,332 shares; 2025Q3: 17,332 shares; 2025Q4: 13,943 shares 13,943$138K3.24%The filing omitted confidential holdings, a later amendment may add them.Timeline
XFORX4 PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 15,557 shares 15,557$62.2K1.45%The filing omitted confidential holdings, a later amendment may add them.Timeline
IKTINHIBIKASE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 16,393 shares; 2025Q1: 16,393 shares; 2025Q2: 16,393 shares; 2025Q3: 16,393 shares; 2025Q4: 28,453 shares 28,453$58.3K1.36%The filing omitted confidential holdings, a later amendment may add them.Timeline
SABSSAB BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 10,935 shares; 2025Q4: 10,527 shares 10,527$39.4K0.92%The filing omitted confidential holdings, a later amendment may add them.Timeline
CNTXCONTEXT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 18,403 shares; 2024Q4: 18,403 shares; 2025Q1: 18,403 shares; 2025Q2: 18,403 shares; 2025Q3: 18,403 shares; 2025Q4: 18,403 shares 18,403$27.1K0.63%The filing omitted confidential holdings, a later amendment may add them.Timeline

How Q4 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000919574-26-000956 base2026-02-13acceptance time not in the bulk data set